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Background: Although enhanced temporal summation (TS) and conditioned pain 
modulation (CPM), as characteristic for central sensitization, has been proved to be 
impaired in different chronic pain populations, the exact nature is still unknown.
Objectives: We examined differences in TS and CPM in 2 chronic pain populations, 
patients with both chronic fatigue syndrome (CFS) and comorbid fibromyalgia (FM) and 
patients with rheumatoid arthritis (RA), and in sedentary, healthy controls, and evaluated 
whether activation of serotonergic descending pathways by acetaminophen improves 
central pain processing.
Study Design: Double-blind randomized controlled trial with cross-over design. 
Methods: Fifty-three women (19 CFS/FM patients, 16 RA patients, and 18 healthy women) 
were randomly allocated to the experimental group (1 g acetaminophen) or the placebo 
group (1 g dextrose). Participants underwent an assessment of endogenous pain inhibition, 
consisting of an evaluation of temporal summation with and without conditioned pain 
modulation (CPM). Seven days later groups were crossed-over. Patients and assessors were 
blinded for the allocation.
Results: After intake of acetaminophen, pain thresholds increased slightly in CFS/FM 
patients, and decreased in the RA and the control group. Temporal summation was reduced 
in the 3 groups and CPM at the shoulder was better overall, however only statistically 
significant for the RA group. Healthy controls showed improved CPM for both finger and 
shoulder after acetaminophen, although not significant. 
Limitations: The influence of acetaminophen on pain processing is inconsistent, 
especially in the patient groups examined. 
Conclusion: This is the first study comparing the influence of acetaminophen on central 
pain processing in healthy controls and patients with CFS/FM and RA. It seems that CFS/
FM patients present more central pain processing abnormalities than RA patients, and that 
acetaminophen may have a limited positive effect on central pain inhibition, but other 
contributors have to be identified and evaluated.
Key words: Chronic pain, sensitization, acetaminophen, conditioned pain modulation, 
temporal summation, chronic fatigue syndrome, fibromyalgia, rheumatoid arthritis
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the hypothesis that activating serotonergic descending 
pathways improves CPM and the suppressing of TS in 
patients’ CS. 
This rationale remains speculative and has not yet 
been evaluated in chronic pain patients. 
Objectives 
Therefore, the manifestation of TS, the efficacy 
of CPM, and the influence of acetaminophen on these 
mechanisms will be evaluated. This will be done in 
healthy controls; in patients with CFS and FM, syn-
dromes that are predominantly characterised by CS; 
and in another chronic pain population, patients with 
RA, in which CS could also play a role besides the pe-
ripheral (articular) problems (10). Here, we report the 
outcome of a double-blind randomized cross-over con-
trolled trial examining these mechanisms in 53 patients. 
Methods
A single-dose, randomized, double-blind, 2-period 
cross-over design was used. The study took place at 
the Research Unit of the University Hospital Antwerp 
(Belgium) and was approved by the ethical committee 
of the University Hospital Antwerp and the Federal 
Agency for Medicines and Health Products (EUDRA CT 
number 2010-020498-17) and is registered by Clinical-
Trials.gov (NCT01154647).
Patients
The present study aimed at enrolling 2 chronic pain 
populations: those with RA and those with a typical 
central sensitization image, patients fulfilling the crite-
ria for both CFS and primary FM.  Furthermore, healthy 
sedentary pain-free subjects were included as controls. 
Each study participant was a woman aged between 23 
and 69 years. The CFS/FM group complied with the diag-
nostic criteria for FM as defined by the American College 
of Rheumatology (24) and the Center of Disease Con-
trol criteria for CFS (25), this means that their pain and 
fatigue complaints could not be the result of a medical 
diagnoses of cancer, RA, multiple sclerosis, psychiatric 
illnesses, etc. At the time of inclusion, healthy control 
subjects could not have any pain complaints. Sedentary 
was defined as having a sedentary job and perform-
ing less than 3 hours of moderate physical activity per 
week. Moderate physical activity was defined as activity 
demanding at least the threefold of the energy spent 
passively (26). In order to preclude confounding factors, 
participants could not be pregnant or until one year 
postnatal and were asked to stop antidepressants and 
Chronic pain is the most debilitating symptom in many medical conditions including fibromyalgia (FM), chronic fatigue syndrome (CFS), chronic 
low back pain, rheumatoid arthritis (RA), osteoarthritis, 
and chronic whiplash. An increasing amount of 
scientific evidence indicates that central sensitization 
(CS) accounts for chronic pain in the majority of these 
patients (1- 6). 
Sensitivity to pain results from the outcome of 
the battle between pain facilitatory and inhibitory 
pathways. One function of the descending inhibitory 
pathway is to “focus” the excitation of the dorsal horn 
neurons by suppressing surrounding neuronal activity 
(7), a role attributed to the conditioned pain modula-
tion (CPM) phenomenon (8). In chronic pain and CS, the 
descending pain-inhibitory pathways, including CPM, 
seem to be malfunctioning, e.g., in patients with CFS, 
FM, osteoarthritis, etc.  (1,2,4). Malfunctioning of CPM 
is however not proven in all chronic pain populations. 
For example, one study reported normal function in RA 
patients (9). However, the symmetrical manifestation 
of RA, the poor relation between the arthritis’s activity 
and symptoms, and the generalized hyperalgesia both 
at articular and non-articular sites for different kinds of 
stimuli are indicative for CS in RA patients (10).
Another characteristic of CS is enhanced wind-up 
of the dorsal horn neurons or temporal summation (TS) 
of second pain (5). Wind-up refers to the progressive 
increase of electrical discharges from the second-order 
neurons in the spinal cord in response to repetitive 
C-fiber stimulation, and is experienced in humans as 
increased pain (11-13). In healthy controls CPM is able 
to soften TS (14), which may protect the central ner-
vous system (CNS) from excessive nociceptive barrage. 
In patients with FM and RA there is already evidence for 
enhanced TS of pain (5,15-17), but the possible contri-
bution of impaired pain inhibition is still unclear. 
Descending control of pain entails an extremely 
sophisticated grouping of CNS actions [reviewed in 
(18)]. Acetaminophen primarily acts centrally: it rein-
forces descending inhibitory pathways (19), namely the 
serotonergic descending pain pathways (20). In addi-
tion, acetaminophen may exert an inhibitory action on 
the enzyme cyclooxygenase in the CNS, involved in the 
transformation of arachnidonic acid to prostaglandins. 
Cyclooxygenase-2 and prostaglandin E2 expression in 
the CNS takes part of the mechanism of CS in those 
with chronic pain (21). The fact that several genotypes 
of the serotonin gen are related to higher levels of pain 
intensity in patients with CS (22,23) further supports 
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other medication 2 weeks prior to study participation, 
not to undertake physical exertion, and to refrain from 
consuming caffeine, alcohol, or nicotine on the day of 
the experiment. For ethical reasons, patients were able 
to take non-opioid pain medication as described in the 
first step of the World Health Organization analgesic 
ladder (NSAID’s and acetaminophen) up to 48 hours 
before the experiment. 
Based on an a priori power analysis we aimed at 
enrolling a total sample size of at least 39 patients. 
Sample size was calculated based on a power analysis, 
calculated with G*Power 3.1.3. An a priori power analy-
sis was performed for the within-between interaction in 
repeated measures ANOVA with 3 groups, 4 measure-
ments (TS with and without CPM, under placebo or 
acetaminophen), an effect size of .25 and a minimum 
power of .90.
Procedure
Before patients were subjected to the experiment, 
they received all the information needed and were 
asked to sign the informed consent. This experiment 
was a double-blind randomized controlled trial (RCT) 
with cross-over design, as presented in Fig. 1. In order 
to evaluate whether activation of serotonergic de-
scending pathways improved pain inhibition, patients 
were allocated to a placebo group or an experimental 
group that received acetaminophen per os. The experi-
ment consisted of an evaluation of the manifestation 
of TS with and without a conditioning stimulus. This 
protocol was repeated in the cross-over design (experi-
mental groups became control group and vice versa) 
with a one-week washout period. 
Fig. 1. Flow diagram of  the study.
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Acetaminophen and Placebo
Both placebo (1g dextrose) and acetaminophen 
(1g acetaminophen) were capsuled in 2 hard gelatin 
capsules, allowing blinding of patients and researchers. 
Capsules were administered per os 30 minutes before 
the assessment of pain inhibition, given the pharma-
cokinetic profile of acetaminophen. Following oral 
administration, acetaminophen is rapidly and almost 
completely absorbed from the gastro-intestinal tract. 
Peak plasma concentrations are attained within 10 – 60 
minutes. It is distributed into most body tissues. Plasma 
protein binding is negligible at usual therapeutic doses 
but increases with increasing doses. The elimination 
half-life varies from about one to 3 hours. Acetamino-
phen is a p-aminophenol derivative that exhibits anal-
gesic and antipyretic activity.
Capsules were delivered by a study nurse who 
coordinated the randomized allocation (by a computer 
program). This way, both the patients and the rater 
remained blinded until the end of the study. At the end 
of the study the efficacy of the blinding was evaluated 
in both patients and rater.
Endogenous Pain Inhibition
The efficacy of endogenous pain inhibition was 
assessed by a procedure of temporal and spatial sum-
mation of noxious stimuli, as described by Cathcart et 
al (14). This procedure evaluates the degree of TS or 
wind-up in response to 10 applications (pulses) of the 
Fisher algometer (Force Dial model FDK 40, Wagner 
Instruments, Greenwich) at a previously defined pres-
sure pain threshold intensity at the dorsal surface of 
the right-hand middle finger midway between the 
first and second distal joints, and at the middle of the 
right-hand side upper trapezius belly. The subjects 
were asked to rate the intensity and unpleasantness 
of the pain intuitively of the first, fifth, and tenth 
pulse on a verbal numerical rating scale (VNRS) (0 = 
no pain to 10 = worst possible pain). CPM was assessed 
by replicating the TS assessment associated with a 
conditioning stimulus for eliciting CPM. The condi-
tioning stimulus was an occlusion cuff at the left arm 
inflated to a painful intensity and maintained at the 
level while TS was elicited. This procedure is explained 
in depth elsewhere and seemed reliable. In healthy 
controls CPM induced by the ischaemic cuff is able to 
dampen TS (14). The same method was previously used 
in chronic whiplash patients (27).
The outcome measure for TS is the difference be-
tween the tenth and the first pain rating score before 
cuff inflation. The measure for CPM is the difference 
between the tenth pain rating score before occlusion 
and the tenth during occlusion. This means that 8 TS 
scores (TS1–TS4: under placebo and TS5–TS8: under ac-
etaminophen) and 4 CPM (CPM1–2: under placebo and 
CPM3–4: under acetaminophen) scores were obtained 
per test site (finger and shoulder) for each participant.
Statistical Analysis
All data were analyzed using the Statistical Pack-
age for Social Sciences 20.0 for Windows (SPSS Inc. 
Headquarters, Chicago, Illinois, USA). Normality of data 
was assessed with the one sample Kolmogorov-Smirnov 
test. Descriptives are presented as means ± standard 
deviations. Baseline characteristics were compared 
between groups with a one-way ANOVA. As age was 
significantly higher in patients with RA, further analy-
ses were corrected for age. Changes in TS and in CPM 
were compared between the 3 groups by repeated 
measures ANCOVAS. Changes in PPT’s between placebo 
and acetaminophen within groups were evaluated 
with paired t-tests and effect sizes were calculated as 
Cohen’s d, with d defined as the difference between 
the 2 means divided by the pooled standard deviation 
for those means. A d-value of .20 is described as small, 
.50 as medium (moderate), and .80 as large (28). 
Significance level was set at 0.05.
Results
Fifty-three volunteers participated in the study 
(19 CFS/FM patients, 16 RA patients, and 18 healthy 
controls), all women between 23 and 69 years old. One 
CFS/FM patient withdrew from the study because she 
forgot the second appointment and did not show up 
at a second attempt. Because the mean age (Table 1) 
was significantly higher in the RA group, analysis of 
the pain scores are age corrected, although this did not 
change the results.
Comparison of Characteristics under Placebo
Pain thresholds at the finger were significantly 
higher in the control group compared to the 2 patient 
groups and pain thresholds at the shoulder were sig-
nificantly lower in the CFS/FM group compared to the 
RA patients and the controls.
Also the threshold for the cuff pressure was sig-
nificantly lower in the CFS/FM group, accompanied 
by higher VNRS scores for the experienced ischemic 
pain. At a VNRS-score of 3 (as defined by Cathcart 
et al [14]), the cuff pressure was again statistically 
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significantly lower compared to the controls and RA 
patients.
A lower TS score was only observed at the shoul-
der in CFS/FM patients compared to the healthy 
controls.
Comparison of Characteristics under 
Acetaminophen
Under acetaminophen the same differences were 
observed, regardless of a similar TS score at the shoul-
der under this condition.
Comparison Acetaminophen versus Placebo 
Condition
PPT’s
It seems that acetaminophen has significant effects 
on PPT’s in the 3 groups, but only in the CFS group did 
it lead to a significant increase of the PPT, as shown in 
Table 2. In the other 2 groups a decrease was observed.
Manifestation of TS
Under placebo, the findings are not consistent 
Table 1. Age and pain score under acetaminophen and placebo.
CFS/FM (n=19 )* RA (n=16) CON (n=18)
Significant differences
Mean SD Mean SD Mean SD
Age 44.58 7.34 54.25 8.36 41.06 14.48 RA   > CON = CFS
PPT finger 6.00 2.26 6.63 2.71 8.50 1.86 CON > CFS = RA
PPT finger 5.80 2.49 6.73 3.09 9.53 2.50 CON > CFS = RA
PPT shoulder 2.05 1.27 4.13 2.36 4.89 1.94 CFS < CON = RA
PPT shoulder 1.83 0.82 4.19 3.04 5.19 2.07 CFS < CON = RA
TS score finger 2.47 1.71 2.19 2.14 2.11 2.00
TS score finger 2.58 2.17 2.72 1.69 1.83 2.73
TS score shoulder 1.95 1.51 1.12 1.54 1.17 1.76
TS score shoulder 0.89 2.89 1.22 1.83 1.22 1.99 CFS < CON
Cuff pressure threshold 100.26 32.34 149.37 63.16 163.33 50.06 CFS < CON = RA
Cuff pressure threshold 102.50 50.30 167.50 84.97 179.72 64.55 CFS < CON = RA
VNRS ischaemic cuff 5.74 1.88 4.50 2.39 3.75 2.32 CFS < CON
VNRS ischaemic cuff 5.56 2.23 4.59 2.32 3.78 2.37 CFS < CON
Cuff pressure at VNRS = 3 60.79 39.97 109.06 65.10 136.94 57.12 CFS < CON = RA
Cuff pressure at VNRS = 3 62.22 45.90 105.63 50.49 153.89 72.79 CFS < CON
CPM score finger -0.05 1.39 0.56 1.14 0.47 1.40
CPM score finger 0.06 0.94 0.72 1.44 -0.11 1.13
CPM score shoulder 0.79 1.36 0.91 1.07 0.58 0.97
CPM score shoulder -0.22 2.21 0.13 1.04 0.42 1.29
(*CFS/FM measurements under placebo: n = 18; TS = Temporal summation, CPM = Conditioned Pain Modulation)
Table 2. Pressure pain thresholds (PPT’s) under acetaminophen and placebo.
Acetaminophen Placebo Significant 
differences
Cohen’s d 
effect sizeMean SD Mean SD
CFS
finger 5.89 2.27 5.80 2.49 0.000 0.038
shoulder 2.00 1.28 1.83 0.82 0.001 0.157
RA
finger 6.63 2.70 6.73 3.09 0.007 -0.034
shoulder 4.13 2.36 4.19 3.04 0.000 -0.022
CON
finger 8.50 1.86 9.53 2.50 0.081 -0.467
shoulder 4.89 1.94 5.19 2.07 0.000 -0.150
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and opposite in the shoulder compared to the finger 
(Figs. 2A and 2B). For the finger there is a significant 
interaction effect (P = 0.039), with increased TS score 
during CPM (ischaemic cuff) in the healthy controls 
and reduced TS scores during CPM in the patient 
groups.
As presented in Figs. 3A and 3B, under acetamino-
phen TS during CPM decreased most of the time in the 
3 groups, suggesting a normal CPM function.
For the shoulder, there is a significant main effect 
for time (P = 0.002).
Temporal summation is always the highest in 
CFS/FM patients, although the differences are not 
significant.  
Fig. 2. Temporal summation (TS) with and without conditioned pain modulation (CPM) under placebo.
Fig. 3. Temporal summation (TS) with and without conditioned pain modulation (CPM) under acetaminophen.
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Efficacy CPM 
For the shoulder CPM was consistently better un-
der acetaminophen. For the RA group the difference 
was significant (P = .026) (Fig. 4).
For the finger, only the control subjects presented 
better CPM function with acetaminophen. In the RA 
patients and the CFS/FM patients there was not a great 
difference between the CPM scores under acetamino-
phen or placebo.
In general, CPM scores are lower (not significant) in 
CFS/FM patients.
Efficacy Blinding
Twenty-five of the 52 patients judged their alloca-
tion correctly, while the assessor judged 28 of the 52 
case correctly. Both figures approach 50%, indicating 
successful blinding.  
discussion
The goal of the present study was to evaluate TS 
and CPM under placebo and acetaminophen condition 
in healthy controls and 2 different chronic pain popula-
tions (i.e., patients with RA and patients with CFS/FM), 
and to compare the different groups and conditions. 
Patients with CFS/FM presented widespread hy-
peralgesia, as evidenced by significantly lower PPT’s 
and cuff pressures, and higher VNRS scores compared 
to healthy controls and even to the patients with RA 
for some variables. Patients with RA were more similar 
to the healthy controls despite the PPT at the finger, 
suggesting primary hyperalgesia (peripheral sensitiza-
tion) rather than widespread hyperalgesia as a sign for 
central sensitization. Furthermore, it is known that RA 
frequently affects finger joints, and persistent synovitis 
is believed to cause not only bone destruction but also 
various deformities of the fingers in the long run. 
Although CFS/FM patients presented overall higher 
TS scores and lower CPM scores compared to the con-
trol group and the RA group, there were no significant 
differences between the 3 groups under placebo and 
acetaminophen. However, the study was not designed 
to compare the differences in TS and CPM between the 
various groups. Hence, it would be premature to make 
conclusions regarding TS and CPM differences between 
groups. In addition, both conditions might be influ-
enced by acetaminophen, expectations, placebo effect, 
etc. Since it is known that the modulation of pain by 
expectations is mediated by top-down endogenous 
pain modulatory systems affecting nociceptive signal 
processing at the earliest stage of the central nervous 
system (29), the placebo effect may have influenced the 
results (cfr. the efficacy of the blinding). Therefore, we 
cannot draw conclusions about the function of CPM in 
CFS/FM and RA, based on the present results. 
Regarding the influence of acetaminophen, PPT’s 
slightly increase in CFS/FM patients and decrease in 
patients with RA and healthy controls. The differences 
are however very small (cfr. effect sizes), as could be 
Fig. 4. Conditioned pain modulation (CPM) under placebo versus acetaminophen.
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expected based on past studies that could not find an 
effect of acetaminophen on pain thresholds (30,31). 
Furthermore, it is not known what difference in pain 
threshold can be called clinically significant. Graphs 
clearly indicate that acetaminophen reduces the effi-
cacy of TS in all groups, leading to consistent lowering 
of the TS scores (significant for the shoulder). Similarly, 
for the shoulder CPM seems to be more efficient under 
acetaminophen, while the findings are inconsistent for 
the finger.
The present study findings indicate that acetamino-
phen has positive effects in suppressing TS of pain. The 
supporting role of acetaminophen in CPM is however 
still unclear because of inconsistent results for the shoul-
der and finger. The observation that CPM was activated 
by acetaminophen if evaluated at the shoulder, but not 
at the finger, may be the consequence of the fact that af-
ter repeated pressure stimuli, the finger became highly 
sensitive in all participants. TS scores are overall higher 
at the finger compared to the shoulder. The majority of 
participants still reported after-sensations of pain due 
to the first TS sequence, when the second TS sequence 
(during the conditioning cuff inflation) was started. This 
way, the second TS sequence did not start at a normal 
baseline, as was the case for the shoulder.  
On the other hand, it is known that pain originating 
in deep soft tissue (like the trapezius muscle) influences 
central pain processing systems more than superficial 
tissue (like the finger) (32). This could explain why CPM 
scores are generally higher at the shoulder compared 
to the finger and why the findings at the finger are 
inconsistent.  
Nevertheless, acetaminophen is efficacious in en-
hancing CPM effect in healthy controls. In RA patients 
and CFS/FM patients, the additional value of acetamin-
ophen is less clear, suggesting that other pathways may 
require stimulation to obtain better endogenous pain 
inhibition. An explanation may be found in the path-
ways that are modulated by acetaminophen. Possibly, 
the serotonergic pathways are not important players in 
the (dis)functioning of CPM. They may contribute partly, 
but other pathways may be of greater importance, like 
for example, the opioid pathways. The latter hypothesis 
is supported by the findings of King et al (33), who re-
ported that the inhibitory effect of CPM is reduced with 
naltrexone, suggesting at least partial dependence of 
inhibition on endogenous opioids. It would therefore 
be interesting to study the opposite, namely the modu-
lation of the function of CPM in chronic pain patients 
by opioid agonists. 
The observation that PPT’s increase in CFS/FM 
patients under acetaminophen may indicate that ac-
etaminophen can be useful for these patients in sup-
pressing pain, but are less likely to fully support endog-
enous pain inhibition. The therapeutic approach may 
therefore require modulation of multiple pathways. 
Further research is however warranted to answer these 
questions.
Finally, it is quite possible that the procedure used 
in this study lead to peripheral sensitization of the fin-
ger, since many participants, both patients and controls, 
complained of pain and after-sensations at the finger 
up to 24 hours after the test (and not at the shoulder). 
The fact that acetaminophen primarily acts centrally by 
reinforcing descending inhibitory pathways (19) may 
explain the lack of a definite effect of acetaminophen 
on CPM at the finger. 
The present study should be interpreted in the 
light of some limitations, opening doors for future 
studies. Although it was interesting to observe such 
differences between finger and shoulder, probably re-
flecting the differences between deep and superficial 
tissue and between more peripheral problems versus 
central abnormalities, future research should reflect 
about using the finger in this protocol to assess CPM. 
Although this may be a limitation, in the meantime 
it may be interesting for the present study in which 
a disease predominantly considered as a peripheral 
condition (RA) is compared to a central disfunctioning 
syndrome (CFS/FM).
Additionally, it remains a question how to as-
sess CPM: mechanical stimuli, thermal stimulation, or 
chemical?
Finally, to preclude interference of the entry phar-
macotherapy of the patients, patients had to refrain 
from antidepressants and other medications for 2 
weeks and pain medication from WHO step 1 for 48 
hours prior to study participation. This was a sufficient 
wash-out period, based on the literature study of 
Smith and Barkin (34), but may have led to withdrawal 
phenomena or a temporary pain exacerbation and to 
exclusion of those patients who could not stop their 
medication.   
To the best of our knowledge, this is the first study 
comparing TS and CPM between different populations 
and under placebo versus acetaminophen condition. 
The findings suggest that serotonergic pathways play 
a role in TS and CPM, but probably only for deeper 
tissues, and it is plausible that other pathways even 
contribute to the (dis)function of central pain process-
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ing. It is clear that this domain remains a complex issue 
and that far more research is warranted to unravel 
the mechanism of endogenous pain inhibition and to 
unravel the possible disfunction. Furthermore, practi-
cal and clinical useful measures for endogenous pain 
inhibition are required.  
conclusion
This cross-over RCT showed that acetaminophen 
may partly support conditioned pain, but that other 
contributors than serotonergic pathways should be 
identified.
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